Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wou… Read more
Rafarma Pharmaceuticals Inc (RAFA) - Total Liabilities
Latest total liabilities as of March 2025: $1.65 Million USD
Based on the latest financial reports, Rafarma Pharmaceuticals Inc (RAFA) has total liabilities worth $1.65 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rafarma Pharmaceuticals Inc - Total Liabilities Trend (2010–2024)
This chart illustrates how Rafarma Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rafarma Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Rafarma Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shearwater Group plc
LSE:SWG
|
UK | GBX10.50 Million |
|
Intercontinental Gold and Metals Ltd
PINK:GXMLF
|
USA | $7.82 Million |
|
Altus Property Ventures Inc
PSE:APVI
|
Philippines | ₱139.99 Million |
|
RUBICN RES
BE:D9V
|
Germany | €2.63 Million |
|
O0K0
F:O0K0
|
Germany | €293.93K |
Liability Composition Analysis (2010–2024)
This chart breaks down Rafarma Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rafarma Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rafarma Pharmaceuticals Inc (2010–2024)
The table below shows the annual total liabilities of Rafarma Pharmaceuticals Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.65 Million | -0.42% |
| 2023-12-31 | $1.65 Million | +0.18% |
| 2023-11-30 | $1.65 Million | -91.92% |
| 2022-12-31 | $20.43 Million | 0.00% |
| 2022-11-30 | $20.43 Million | +2.96% |
| 2021-12-31 | $19.84 Million | 0.00% |
| 2021-11-30 | $19.84 Million | +7.01% |
| 2020-12-31 | $18.54 Million | 0.00% |
| 2020-11-30 | $18.54 Million | +62.66% |
| 2019-12-31 | $11.40 Million | 0.00% |
| 2019-11-30 | $11.40 Million | +3469.46% |
| 2018-12-31 | $319.31K | 0.00% |
| 2018-11-30 | $319.31K | +5.00% |
| 2017-12-31 | $304.11K | 0.00% |
| 2017-11-30 | $304.11K | +6.91% |
| 2014-12-31 | $284.45K | 0.00% |
| 2014-11-30 | $284.45K | -84.18% |
| 2013-12-31 | $1.80 Million | 0.00% |
| 2013-11-30 | $1.80 Million | +649.28% |
| 2011-11-30 | $240.04K | +3.85% |
| 2010-11-30 | $231.15K | -- |